Publications

  1. Costello BA, Borad MJ, Qi Y, Kim GP, Northfelt DW, Erlichman C, Alberts SR. Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors. Invest New Drugs. 2014 Aug; 32(4):710-6. Epub 2014 Apr 18.
    View PubMed
  2. Laronga C, Gray JE, Siegel EM, Lee JH, Fulp WJ, Fletcher M, Schreiber F, Brown R, Levine R, Cartwright T, Abesada-Terk G Jr, Kim G, Alemany C, Faig D, Sharp P, Markham MJ, Shibata D, Malafa M, Jacobsen PB. Florida Initiative for Quality Cancer Care: Improvements in Breast Cancer Quality Indicators During a 3-Year Interval. J Am Coll Surg. 2014 Jul 01.
    View PubMed
  3. Tanvetyanon T, Lee JH, Fulp WJ, Schreiber F, Brown RH, Levine RM, Cartwright TH, Abesada-Terk G Jr, Kim GP, Alemany C, Faig D, Sharp PV, Markham MJ, Malafa M, Jacobsen PB. Changes in the care of non-small-cell lung cancer after audit and feedback: the Florida initiative for quality cancer care. J Oncol Pract. 2014 Jul; 10(4):e247-54. Epub 2014 Apr 15.
    View PubMed
  4. Srivastava G, Renfro LA, Behrens RJ, Lopatin M, Chao C, Soori GS, Dakhil SR, Mowat RB, Kuebler JP, Kim G, Mazurczak M, Lee M, Alberts SR. Prospective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patients. Oncologist. 2014 May; 19(5):492-7. Epub 2014 Apr 07.
    View PubMed
  5. Van Loon K, Espinoza AM, Fogelman DR, Wolff RA, Javle MM, Iyer RV, Picozzi VJ, Martin LK, Bekaii-Saab T, Tempero MA, Foster NR, Kim GP, Ko AH. Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas. 2014 Apr; 43(3):343-9.
    View PubMed
  6. Siegel EM, Jacobsen PB, Lee JH, Malafa M, Fulp W, Fletcher M, Smith JC, Brown R, Levine R, Cartwright T, Abesada-Terk G Jr, Kim G, Alemany C, Faig D, Sharp P, Markham MJ, Shibata D. Florida Initiative for Quality Cancer Care: improvements on colorectal cancer quality of care indicators during a 3-year interval. J Am Coll Surg. 2014 Jan; 218(1):16-25.e1-4. Epub 2013 Nov 23
    View PubMed
  7. Peterson JL, Vallow LA, Johnson DW, Heckman MG, Diehl NN, Smith AA, Tzou KS, Paz-Fumagalli R, Kim S, Ko SJ, Daugherty LC, Kim GP, Brown N, Mori KW, Buskirk SJ. Complications after 90Y microsphere radioembolization for unresectable hepatic tumors: An evaluation of 112 patients. Brachytherapy. 2013 Nov-Dec; 12(6):573-9. Epub 2013 Aug 14
    View PubMed
  8. Alberts SR, Reid JM, Morlan BW, Farr GH Jr, Camoriano JK, Johnson DB, Enger JR, Seay TE, Kim GP. Gemcitabine and docetaxel for hepatocellular carcinoma: a phase II North Central Cancer Treatment Group clinical trial. Am J Clin Oncol. 2012 Oct; 35(5):418-23.
    View PubMed
  9. Rocha Lima CM, Lin EH, Kim GP, Giguere JK, Marshall J, Zalupski M, Papageorgio C, Auber ML, Kaleta R, McHenry MB, Trifan OC, Philip PA. A phase 2 trial of ixabepilone plus cetuximab in first-line treatment of metastatic pancreatic cancer. Gastrointest Cancer Res. 2012 Sep; 5(5):155-60.
    View PubMed
  10. Alberts SR, Fitch TR, Kim GP, Morlan BW, Dakhil SR, Gross HM, Nair S. Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II North Central Cancer Treatment Group Clinical Trial. Am J Clin Oncol. 2012 Aug; 35(4):329-33.
    View PubMed
  11. Siegel EM, Jacobsen PB, Malafa M, Fulp W, Fletcher M, Lee JH, Smith JC, Brown R, Levine R, Cartwright T, Abesada-Terk G Jr, Kim G, Alemany C, Faig D, Sharp P, Markham MJ, Shibata D. Evaluating the quality of colorectal cancer care in the state of Florida: results from the Florida Initiative for Quality Cancer Care. J Oncol Pract. 2012 Jul; 8(4):239-45. Epub 2012 Jun 12.
    View PubMed
  12. Panjala C, Nguyen JH, Al-Hajjaj AN, Rosser BA, Nakhleh RE, Bridges MD, Ko SJ, Buskirk SJ, Kim GP, Harnois DM. Impact of neoadjuvant chemoradiation on the tumor burden before liver transplantation for unresectable cholangiocarcinoma. Liver Transpl. 2012 May; 18(5):594-601.
    View PubMed
  13. Sinicrope FA, Foster NR, Yoon HH, Smyrk TC, Kim GP, Allegra CJ, Yothers G, Nikcevich DA, Sargent DJ. Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials. J Clin Oncol. 2012 Feb 1; 30(4):406-12. Epub 2011 Dec 27.
    View PubMed
  14. Kim GP, Mahoney MR, Szydlo D, Mok TS, Marshke R, Holen K, Picus J, Boyer M, Pitot HC, Rubin J, Philip PA, Nowak A, Wright JJ, Erlichman C. An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. Invest New Drugs. 2012 Feb; 30(1):387-94. Epub 2010 Sep 14.
    View PubMed
  15. Kim GP. Aflibercept trial is a milestone for patients with metastatic colorectal cancer. Community Oncol. 2012; 9(4):118-9.
  16. Tanvetyanon T, Corman M, Lee JH, Fulp WJ, Schreiber F, Brown RH, Levine RM, Cartwright TH, Abesada-Terk G, Kim GP, Alemany C, Faig D, Sharp PV, Markham MJ, Bepler G, Siegel E, Shibata D, Malafa M, Jacobsen PB. Quality of care in non-small-cell lung cancer: findings from 11 oncology practices in Florida. J Oncol Pract. 2011 Nov; 7(6):e25-31.
    View PubMed
  17. Jacobsen PB, Shibata D, Siegel EM, Lee JH, Fulp WJ, Alemany C, Abesada-Terk G Jr, Brown R, Cartwright T, Faig D, Kim G, Levine R, Markham MJ, Schreiber F, Sharp P, Malafa M. Evaluating the quality of psychosocial care in outpatient medical oncology settings using performance indicators. Psychooncology. 2011 Nov; 20(11):1221-7. Epub 2010 Sep 27.
    View PubMed
  18. Gray JE, Laronga C, Siegel EM, Lee JH, Fulp WJ, Fletcher M, Schreiber F, Brown R, Levine R, Cartwright T, Abesada-Terk G Jr, Kim G, Alemany C, Faig D, Sharp P, Markham MJ, Shibata D, Malafa M, Jacobsen PB. Degree of variability in performance on breast cancer quality indicators: findings from the Florida initiative for quality cancer care. J Oncol Pract. 2011 Jul; 7(4):247-51.
    View PubMed
  19. Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, Kim GP, Yothers G, Allegra C, Moore MJ, Gallinger S, Sargent DJ. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst. 2011 Jun 8; 103(11):863-75. Epub 2011 May 19.
    View PubMed
  20. Begum R, Harnois D, Satyanarayana R, Krishna M, Halling KC, Kim GP, Nguyen JH, Keaveny AP. Retransplantation for donor-derived neuroendocrine tumor. Liver Transpl. 2011 Jan; 17(1):83-7.
    View PubMed
  21. McWilliams RR, Matsumoto ME, Burch PA, Kim GP, Halfdanarson TR, de Andrade M, Reid-Lombardo K, Bamlet WR. Obesity adversely affects survival in pancreatic cancer patients. Cancer. 2010 Nov 1; 116(21):5054-62.
    View PubMed
  22. Lubner SJ, Mahoney MR, Kolesar JL, Loconte NK, Kim GP, Pitot HC, Philip PA, Picus J, Yong WP, Horvath L, Van Hazel G, Erlichman CE, Holen KD. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol. 2010 Jul 20; 28(21):3491-7. Epub 2010 Jun 07.
    View PubMed
  23. Panjala C, Senecal DL, Bridges MD, Kim GP, Nakhleh RE, Nguyen JH, Harnois DM. The diagnostic conundrum and liver transplantation outcome for combined hepatocellular-cholangiocarcinoma. Am J Transplant. 2010 May; 10(5):1263-7.
    View PubMed
  24. Kim GP, Sargent DJ, Mahoney MR, Rowland KM Jr, Philip PA, Mitchell E, Mathews AP, Fitch TR, Goldberg RM, Alberts SR, Pitot HC. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. J Clin Oncol. 2009 Jun 10; 27(17):2848-54. Epub 2009 Apr 20.
    View PubMed
  25. Stauffer JA, Dougherty MK, Kim GP, Nguyen JH. Interposition graft with polytetrafluoroethylene for mesenteric and portal vein reconstruction after pancreaticoduodenectomy. Br J Surg. 2009 Mar; 96(3):247-52.
    View PubMed
  26. Corsini MM, Miller RC, Haddock MG, Donohue JH, Farnell MB, Nagorney DM, Jatoi A, McWilliams RR, Kim GP, Bhatia S, Iott MJ, Gunderson LL. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005). J Clin Oncol. 2008 Jul 20; 26(21):3511-6.
    View PubMed
  27. Kim GP, Grothey A. Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab. Biologics. 2008 Jun; 2(2):223-8.
    View PubMed
  28. Kim G, Foster N, Oberg A, Jaslowksi A, Alberts S, Flynn P, Dakhil S, Mowat R, Garneau S. NCCTG Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma, N034A. J Clin Oncol. 2008.
    View PubMed
  29. Kim GP. Predictive markers in colorectal cancer. Seminars in Colon and Rectal Surgery. 2008; 19(4):231-8.
    View PubMed
  30. Bonatti H, Huguet K, McLaughlin S, Stockland A, Aranda-Michel J, Al Haddad M, Dougherty M, Fitzpatrick P, Kim G, Martin K, Hinder R, Nguyen JH. Whipple's procedure in a renal transplant recipient with polycystic liver disease. JOP. 2008; 9(4):515-9. Epub 2008 Jul 10.
    View PubMed
  31. Al-Haddad M, Martin JK, Nguyen J, Pungpapong S, Raimondo M, Woodward T, Kim G, Noh K, Wallace MB. Vascular resection and reconstruction for pancreatic malignancy: a single center survival study. J Gastrointest Surg. 2007 Sep; 11(9):1168-74. Epub 2007 Jul 14.
    View PubMed
  32. Alberts SR, Kim GP, Mahoney MR, Gornet MK, Rubin J, Ames M, Goetz MP, Weinshilboum RM, Nicol SJ, Goldberg RM. Pemetrexed and oxaliplatin for metastatic colorectal cancer: results of a phase I Mayo Cancer Center Research Consortium trial, MC0248. Clin Colorectal Cancer. 2007 Jul; 6(8):572-7.
    View PubMed
  33. Alberts SR, Gores GJ, Kim GP, Roberts LR, Kendrick ML, Rosen CB, Chari ST, Martenson JA. Treatment options for hepatobiliary and pancreatic cancer. Mayo Clin Proc. 2007 May; 82(5):628-37.
    View PubMed
  34. Kim GP, Erlichman C. Oxaliplatin in the treatment of colorectal cancer. Expert Opin Drug Metab Toxicol. 2007 Apr; 3(2):281-94.
    View PubMed
  35. Kim GP, Colangelo LH, Wieand HS, Paik S, Kirsch IR, Wolmark N, Allegra CJ, National Cancer Institute. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol. 2007 Mar 1; 25(7):767-72.
    View PubMed
  36. Pilot HC, Kim GP, Rowland KM, Sargent DJ, Philip PA, Mitchell EP, Goldberg RM, Alberts SR. A randomized phase III equivalence trial of irinotecan (CPT-11) versus oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) in patients with advanced colorectal cancer previously treated with 5FU. Manuscript in preparation. 2007.
  37. Kim GP, Philip PA, Mahoney MR, Pitot HC, Fitch T, Picus J, Erlichman C. Phase II trial of PS-341 in unresectable hepatocellular carcinoma. Manuscript in preparation. 2007.
  38. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, Erlichman C. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol. 2006 Jul 1; 24(19):3069-74.
    View PubMed
  39. Kim GP, Grothey A. Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathway. Clin Colorectal Cancer. 2005 Nov; 5 Suppl 2:S89-97.
    View PubMed
  40. Alberts SR, Foster NR, Morton RF, Kugler J, Schaefer P, Wiesenfeld M, Fitch TR, Steen P, Kim GP, Gill S. PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study. Ann Oncol. 2005 Oct; 16(10):1654-61. Epub 2005 Aug 05.
    View PubMed
  41. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, Erlichman C. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol. 2005 Sep 20; 23(27):6657-63.
    View PubMed
  42. Loprinzi CL, Levitt R, Barton DL, Sloan JA, Atherton PJ, Smith DJ, Dakhil SR, Moore DF Jr, Krook JE, Rowland KM Jr, Mazurczak MA, Berg AR, Kim GP, North Central Cancer Treatment Group. Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group trial. Cancer. 2005 Jul 1; 104(1):176-82.
    View PubMed
  43. He G, Howard J, Le M, Partyka L, Li B, Kim G, Hess R, Bryie R, Lee R, Rustomji S, Pepper J, Kail M, Helix M, Elder RB, Jansen DS, Harff NE, Prairie JF, Daniel ES, Gilbert BK. Self-aligned InP DHBT with f(T) and f(max) over 300 GHz in a new manufacturable technology. IEEE Electron Device Lett. 2004 Aug; 25(8):520-2.
    View PubMed
  44. Allegra CJ, Kim G, Kirsch IR. Microsatellite instability in colon cancer. N Engl J Med. 2003 Oct 30; 349(18):1774-5.
    View PubMed
  45. Allegra CJ, Paik S, Colangelo LH, Parr AL, Kirsch I, Kim G, Klein P, Johnston PG, Wolmark N, Wieand HS. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol. 2003 Jan 15; 21(2):241-50.
    View PubMed
  46. Sausville EA, El-Sayed Y, Monga M, Kim GP. Signal transduction directed cancer treatments. Annual Review of Pharmacology & Toxicology. 2002.
  47. Yoon SJ, Heo DS, Kang SH, Lee KH, Kim GP, Lee JA, Bang YJ, Kim NK. Natural killer cell activity depression in peripheral blood and ascites from gastric cancer patients with high TGF-beta 1 expression. Anticancer Research. 1998; 18: 1591-6.
  48. Kramer R, Zahker J, Kim G. Role of glutathione redox cycle in acquired and de novo multidrug resistance. Science. 1988;214:694-7.